Summary

The global liver fibrosis treatment market is expected to reach USD 43.42 billion by 2032 from USD 18.56 billion in 2024, growing at a substantial CAGR of 11.3% in the forecast period of 2025 to 2032.

Market Segmentation:
Global Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada and Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, and Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Israel and rest of Middle East and Africa) - Industry Trends & Forecast To 2032
Overview of Global Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the global liver fibrosis treatment market are listed below:
• Gilead Sciences, Inc.
• AbbVie Inc.
• Intercept Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharma
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 130
1.1 OBJECTIVES OF THE STUDY 130
1.2 MARKET DEFINITION 130
1.3 OVERVIEW OF THE GLOBAL LIVER FIBROSIS TREATMENT MARKET 130
1.4 CURRENCY AND PRICING 132
1.5 LIMITATIONS 132
1.6 MARKETS COVERED 133
2 MARKET SEGMENTATION 137
2.1 MARKETS COVERED 137
2.2 GEOGRAPHICAL SCOPE 138
2.3 YEARS CONSIDERED FOR THE STUDY 139
2.4 DBMR TRIPOD DATA VALIDATION MODEL 140
2.5 MULTIVARIATE MODELLING 143
2.6 TREATMENT TYPE LIFELINE CURVE 144
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 145
2.8 DBMR MARKET POSITION GRID 146
2.9 MARKET END USER COVERAGE GRID 147
2.10 VENDOR SHARE ANALYSIS 148
2.11 SECONDARY SOURCES 149
2.12 ASSUMPTIONS 149
3 EXECUTIVE SUMMARY 150
4 PREMIUM INSIGHTS 154
4.1 PESTAL ANALYSIS 159
4.2 PORTERS FIVE FORCES ANALYSIS 160
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY 161
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY 162
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY 164
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY 165
4.3 EPIDEMIOLOGY 167
4.3.1 INCIDENCE OF ALL BY GENDER 167
4.3.2 TREATMENT RATE 167
4.3.3 TREATMENT RATE 168
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 168
4.3.5 PATIENT TREATMENT SUCCESS RATES 169
4.4 MARKETED DRUG ANALYSIS 170
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 175
4.5.1 PATIENT FLOW DIAGRAM 175
4.5.2 KEY PRICING STRATEGIES 176
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES 178
5 GLOBAL LIVER FIBROSIS TREATMENT MARKET: REGULATIONS 180
6 MARKET OVERVIEW 183
6.1 DRIVERS 185
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES 185
6.1.2 RISING CONSUMPTION OF ALCOHOL 185
6.1.3 RISING LIVER TRANSPLANTATION RATES 186
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH 187
6.2 RESTRAINTS 188
6.2.1 LIMITED AWARENESS OF LIVER DISEASES 188
6.2.2 REGULATORY CHALLENGES 188
6.3 OPPORTUNITIES 190
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT 190
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT 190
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS 191
6.4 CHALLENGES 193
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS 193
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE 193
7 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE 195
7.1 OVERVIEW 196
7.2 MEDICATION 199
7.2.1 ANTIVIRAL AGENTS 201
7.2.1.1 VELPATASVIR/SOFOSBUVIR 201
7.2.1.2 TENOFOVIR 201
7.2.1.3 LEDIPASVIR/SOFOSBUVIR 201
7.2.1.4 SOFOSBUVIR 201
7.2.1.5 ENTECAVIR 201
7.2.2 ANTIFIBROTIC AGENTS 203
7.2.2.1 OBETICHOLIC ACID 203
7.2.2.2 TGF-Β INHIBITORS 203
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS 203
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS 203
7.2.2.5 OTHERS 203
7.2.3 ANTI-INFLAMMATORY DRUGS 205
7.2.3.1 CORTICOSTEROIDS 205
7.2.3.1.1 PREDNISONE 205
7.2.3.1.2 DEXAMETHASONE 205
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS 206
7.2.3.2.1 INFLIXIMAB 206
7.2.3.2.2 ETANERCEPT 206
7.2.3.3 INTERLEUKIN (IL) INHIBITORS 207
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB) 207
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA) 207
7.2.4 IMMUNOSUPPRESSANTS 209
7.2.4.1 MYCOPHENOLATE MOFETIL 209
7.2.4.2 TACROLIMUS 209
7.2.4.3 CYCLOSPORINE 209
7.2.5 MARKETED DRUGS 210
7.2.5.1 VELPATASVIR/SOFOSBUVIR 210
7.2.5.2 TENOFOVIR 210
7.2.5.3 LEDIPASVIR/SOFOSBUVIR 210
7.2.5.4 OBETICHOLIC ACID (OCA) 211
7.2.5.5 SOFOSBUVIR 211
7.2.5.6 PIRFENIDONE 211
7.2.5.7 OTHERS 211
7.2.6 PIPELINE DRUGS 211
7.2.7 BRANDED DRUGS 212
7.2.7.1 EPCLUSA 212
7.2.7.2 VIREAD AND VEMLIDY 212
7.2.7.3 OCALIVA 212
7.2.7.4 HARVONI 213
7.2.7.5 SOVALDI 213
7.2.7.6 BARACLUDE 213
7.2.7.7 ACTOS 213
7.2.7.8 OTHERS 213
7.2.8 GENERIC DRUGS 213
7.2.9 ORAL 213
7.2.10 PARENTERAL 213
7.2.11 OTHERS 213
7.3 SURGERY/THERAPY 214
7.3.1 LIVER TRANSPLANTATION 215
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT) 215
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT) 215
7.3.4 SPLIT LIVER TRANSPLANTATION 215
7.3.5 DOMINO LIVER TRANSPLANT 215
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES 216
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL) 216
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) 216
7.3.6.3 LIVER ABLATION PROCEDURES 216
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA) 216
7.3.6.3.2 MICROWAVE ABLATION (MWA) 216
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION) 217
7.3.7.1 SEGMENTAL RESECTION 217
7.3.7.2 LOBECTOMY 217
7.3.7.3 WEDGE RESECTION 217
7.3.8 CELL-BASED THERAPY 218
7.3.8.1 STEM CELL THERAPY 218
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS) 218
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS) 218
7.3.8.2 GENE THERAPY 219
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION 219
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS 219
7.3.8.2.3 SIRNA-BASED THERAPIES 219
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS 219
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS 220
7.3.8.2.4.2 EMRICASAN 220
7.3.8.2.4.3 PENTOXIFYLLINE 220
7.3.8.2.4.4 LOSARTAN 220
7.3.8.2.4.5 METHYL FERULIC ACID 220
7.3.8.2.4.6 OTHERS 220
7.4 OTHERS 220
8 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY STAGES 221
8.1 OVERVIEW 222
8.2 F2 225
8.3 F1 226
8.4 F3 226
8.5 F4 227
9 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY INDICATION 228
9.1 OVERVIEW 229
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) 232
9.3 HEPATITIS B & C-INDUCED FIBROSIS 233
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS 233
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS 233
9.4 ALCOHOLIC LIVER DISEASE (ALD) 234
9.5 AUTOIMMUNE LIVER DISEASES 235
9.5.1 AUTOIMMUNE HEPATITIS (AIH) 236
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC) 236
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC) 236
9.6 GENETIC DISORDERS 236
9.6.1 HEMOCHROMATOSIS 237
9.6.2 WILSON’S DISEASE 237
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY 237
9.7 OTHERS 237
10 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY GENDER 238
10.1 OVERVIEW 239
10.2 MALE 242
10.2.1 40-55 YEARS 243
10.2.2 ABOVE 55 YEARS 243
10.2.3 BELOW 40 YEARS 243
10.3 FEMALE 244
10.3.1 ABOVE 55 YEARS 244
10.3.2 40-55 YEARS 244
10.3.3 BELOW 40 YEARS 244
11 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY END USER 245
11.1 OVERVIEW 246
11.2 HOSPITALS 249
11.2.1 PUBLIC HOSPITALS 250
11.2.2 PRIVATE HOSPITALS 250
11.3 SPECIALTY CLINICS 250
11.3.1 HEPATOLOGY CLINICS 251
11.3.2 GASTROENTEROLOGY CLINICS 251
11.4 CLINICS 251
11.5 AMBULATORY AND RESEARCH CENTERS 252
11.6 OTHERS 253
12 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 254
12.1 OVERVIEW 255
12.2 DIRECT TENDER 258
12.2.1 RETAIL SALES 259
12.2.1.1 HOSPITAL PHARMACY 259
12.2.1.2 RETAIL PHARMACY 259
12.2.1.3 ONLINE PHARMACY 259
13 GLOBAL LIVER FIBROSIS TREATMENT MARKET, BY REGION 260
13.1 OVERVIEW 261
13.2 NORTH AMERICA 265
13.2.1 U.S. 285
13.2.2 CANADA 304
13.2.3 MEXICO 320
13.3 EUROPE 336
13.3.1 GERMANY 356
13.3.2 FRANCE 375
13.3.3 U.K. 393
13.3.4 ITALY 411
13.3.5 SPAIN 429
13.3.6 SWITZERLAND 447
13.3.7 RUSSIA 465
13.3.8 BELGIUM 482
13.3.9 NETHERLANDS 499
13.3.10 TURKEY 517
13.3.11 POLAND 533
13.3.12 SWEDEN 549
13.3.13 NORWAY 565
13.3.14 DENMARK 581
13.3.15 FINLAND 597
13.3.16 REST OF EUROPE 613
13.4 ASIA-PACIFIC 614
13.4.1 CHINA 634
13.4.2 JAPAN 650
13.4.3 INDIA 666
13.4.4 SOUTH KOREA 682
13.4.5 AUSTRALIA 698
13.4.6 SINGAPORE 714
13.4.7 THAILAND 729
13.4.8 INDONESIA 744
13.4.9 MALAYSIA 759
13.4.10 TAIWAN 774
13.4.11 NEW ZEALAND 789
13.4.12 PHILIPPINES 804
13.4.13 VIETNAM 819
13.4.14 REST OF ASIA-PACIFIC 834
13.5 SOUTH AMERICA 835
13.5.1 BRAZIL 853
13.5.2 ARGENTINA 869
13.5.3 REST OF SOUTH AMERICA 885
13.6 MIDDLE EAST AND AFRICA 886
13.6.1 SOUTH AFRICA 903
13.6.2 SAUDI ARABIA 919
13.6.3 U.A.E 935
13.6.4 EGYPT 950
13.6.5 ISRAEL 965
13.6.6 KUWAIT 980
13.6.7 QATAR 995
13.6.8 OMAN 1010
13.6.9 REST OF MIDDLE EAST AND AFRICA 1025
14 GLOBAL LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE 1026
14.1 COMPANY SHARE ANALYSIS: GLOBAL 1026
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 1027
14.3 COMPANY SHARE ANALYSIS: EUROPE 1028
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1029
15 SWOT ANALYSIS 1030
16 COMPANY PROFILES 1031
16.1 GILEAD SCIENCES, INC. 1031
16.1.1 COMPANY SNAPSHOT 1031
16.1.2 REVENUE ANALYSIS 1032
16.1.3 COMPANY SHARE ANALYSIS 1032
16.1.4 PRODUCT PORTFOLIO 1033
16.1.5 RECENT DEVELOPMENT/NEWS 1037
16.2 ABBVIE, INC. 1039
16.2.1 COMPANY SNAPSHOT 1039
16.2.2 REVENUE ANALYSIS 1039
16.2.3 COMPANY SHARE ANALYSIS 1040
16.2.4 PRODUCT PORTFOLIO 1040
16.2.5 RECENT DEVELOPMENT 1040
16.3 MERCK & CO, INC. 1041
16.3.1 COMPANY SNAPSHOT 1041
16.3.2 REVENUE ANALYSIS 1042
16.3.3 COMPANY SHARE ANALYSIS 1042
16.3.4 PRODUCT PORTFOLIO 1042
16.3.5 RECENT DEVELOPMENT 1042
16.4 NOVARTIS AG 1043
16.4.1 COMPANY SNAPSHOTS 1043
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 1044
16.4.3 COMPANY SHARE ANALYSIS 1044
16.4.4 PRODUCT PORTFOLIO 1044
16.4.5 PIPELINE PRODUCT PORTFOLIO 1045
16.4.6 RECENT DEVELOPMENT 1045
16.5 INTERCEPT PHARMACEUTICALS, INC. 1046
16.5.1 COMPANY SNAPSHOTS 1046
16.5.2 COMPANY SHARE ANALYSIS 1046
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 1046
16.5.4 PRODUCT PORTFOLIO 1047
16.5.5 PIPELINE PRODUCT PORTFOLIO 1047
16.5.6 RECENT NEWS 1048
16.6 ABBOTT 1049
16.6.1 COMPANY SNAPSHOT 1049
16.6.2 REVENUE ANALYSIS 1049
16.6.3 PRODUCT PORTFOLIO 1050
16.6.4 1.1.5 RECENT DEVELOPMENT 1050
16.7 ALIGOS THERAPEUTICS 1051
16.7.1 COMPANY SNAPSHOT 1051
16.7.2 REVENUE ANALYSIS 1051
16.7.3 PRODUCT PORTFOLIO 1052
16.7.4 RECENT DEVELOPMENT 1052
16.8 ALNICHE LIFE SCIENCES PVT. LTD. 1054
16.8.1 COMPANY SNAPSHOT 1054
16.8.2 PRODUCT PORTFOLIO 1054
16.8.3 RECENT DEVELOPMENT 1055
16.9 ALENTIS THERAPEUTICS AG 1056
16.9.1 COMPANY SNAPSHOT 1056
16.9.2 PIPELINE PRODUCT PORTFOLIO 1056
16.9.3 RECENT DEVELOPMENT 1056
16.10 ADALTA LIMITED 1057
16.10.1 COMPANY SNAPSHOT 1057
16.10.2 REVENUE ANALYSIS 1057
16.10.3 PIPELINE PRODUCT PORTFOLIO 1058
16.10.4 RECENT NEWS 1058
16.11 AKERO THERAPEUTICS, INC. 1059
16.11.1 COMPANY SNAPSHOT 1059
16.11.2 REVENUE ANALYSIS 1059
16.11.3 PIPELINE PRODUCT PORTFOLIO 1059
16.11.4 RECENT DEVELOPMENT 1060
16.12 BRISTOL-MYERS SQUIBB 1061
16.12.1 COMPANY SNAPSHOT 1061
16.12.2 REVENUE ANALYSIS 1061
16.12.3 PRODUCT PORTFOLIO 1062
16.12.4 RECENT DEVELOPMENT 1062
16.13 CALLIDITAS THERAPEUTICS AB 1063
16.13.1 COMPANY SNAPSHOT 1063
16.13.2 PIPELINE PRODUCT PORTFOLIO 1063
16.13.3 RECENT DEVELOPMENT 1064
16.14 CUREVAC SE 1065
16.14.1 COMPANY SNAPSHOT 1065
16.14.2 REVENUE ANALYSIS 1065
16.14.3 PRODUCT PORTFOLIO 1066
16.14.4 RECENT DEVELOPMENT 1066
16.15 CONATUSPHARMA 1067
16.15.1 COMPANY SNAPSHOT 1067
16.15.2 PRODUCT PORTFOLIO 1067
16.15.3 RECENT DEVELOPMENT/NEWS 1067
16.16 ENANTA PHARMACEUTICALS, INC. 1068
16.16.1 COMPANY SNAPSHOT 1068
16.16.2 REVENUE ANALYSIS 1068
16.16.3 PRODUCT PORTFOLIO 1069
16.16.4 RECENT DEVELOPMENT 1069
16.17 ECHOSENS 1070
16.17.1 COMPANY SNAPSHOT 1070
16.17.2 PRODUCT PORTFOLIO 1070
16.17.3 RECENT DEVELOPMENT/NEWS 1071
16.18 F. HOFFMANN-LA ROCHE LTD 1073
16.18.1 COMPANY SNAPSHOT 1073
16.18.2 REVENUE ANALYSIS 1073
16.18.3 COMPANY SHARE ANALYSIS 1074
16.18.4 PRODUCT PORTFOLIO 1074
16.18.5 RECENT DEVELOPMENT 1074
16.19 GALECTO BIOTECH 1075
16.19.1 COMPANY SNAPSHOT 1075
16.19.2 REVENUE ANALYSIS 1075
16.19.3 PIPELINE PRODUCT PORTFOLIO 1075
16.19.4 RECENT DEVELOPMENT/NEWS 1075
16.20 GALECTIN THERAPEUTICS, INC. 1077
16.20.1 COMPANY SNAPSHOTS 1077
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS 1077
16.20.3 PIPELINE PRODUCT PORTFOLIO 1077
16.20.4 RECENT DEVELOPMENT 1078
16.21 GYRE THERAPEUTICS, INC. 1080
16.21.1 COMPANY SNAPSHOT 1080
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 1081
16.21.3 PRODUCT PORTFOLIO 1081
16.21.4 RECENT DEVELOPMENT/NEWS 1082
16.22 GENFIT SA 1083
16.22.1 COMPANY SNAPSHOTS 1083
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 1083
16.22.3 PIPELINE PRODUCT PORTFOLIO 1084
16.22.4 RECENT DEVELOPMENT 1084
16.23 HEPION PHARMACEUTICALS 1086
16.23.1 COMPANY SNAPSHOT 1086
16.23.2 REVENUE ANALYSIS 1086
16.23.3 PIPELINE PORTFOLIO 1086
16.23.4 RECENT DEVELOPMENT 1086
16.24 IPSEN PHARMA 1088
16.24.1 COMPANY SNAPSHOT 1088
16.24.2 REVENUE ANALYSIS 1088
16.24.3 PIPELINE PRODUCT PORTFOLIO 1089
16.24.4 RECENT NEWS/DEVELOPMENTS 1089
16.25 LA RENON HEALTHCARE PVT. LTD. 1091
16.25.1 COMPANY SNAPSHOT 1091
16.25.2 PRODUCT PORTFOLIO 1091
16.25.3 RECENT DEVELOPMENT 1093
16.26 MADRIGAL PHARMACEUTICALS 1094
16.26.1 COMPANY SNAPSHOTS 1094
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 1094
16.26.3 PRODUCT PORTFOLIO 1094
16.26.4 RECENT DEVELOPMENT 1095
16.27 NOVO NORDISK A/S 1096
16.27.1 COMPANY SNAPSHOT 1096
16.27.2 REVENUE ANALYSIS 1096
16.27.3 PIPELINE PRODUCT PORTFOLIO 1097
16.27.4 RECENT DEVELOPMENT 1097
16.28 NOVOMEDIX 1098
16.28.1 COMPANY SNAPSHOT 1098
16.28.2 PIPELINE PRODUCT PORTFOLIO 1098
16.28.3 RECENT DEVELOPMENT 1098
16.29 PILANT THERAPEUTICS, INC. 1099
16.29.1 COMPANY SNAPSHOT 1099
16.29.2 REVENUE ANALYSIS 1099
16.29.3 PIPELINE PRODUCT PORTFOLIO 1100
16.29.4 RECENT NEWS 1100
16.30 PFIZER INC. 1101
16.30.1 COMPANY SNAPSHOT 1101
16.30.2 REVENUE ANALYSIS 1101
16.30.3 PIPELINE PRODUCT PORTFOLIO 1102
16.30.4 RECENT DEVELOPMENT/NEWS 1102
16.31 SAGIMET BIOSCIENCES 1103
16.31.1 COMPANY SNAPSHOTS 1103
16.31.2 REVENUE ANALYSIS 1103
16.31.3 1.1.4 PRODUCT PORTFOLIO 1103
16.31.4 RECENT DEVELOPMENT/NEWS 1104
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED 1105
16.32.1 COMPANY SNAPSHOT 1105
16.32.2 REVENUE ANALYSIS 1106
16.32.3 PIPELINE PRODUCT PORTFOLIO 1106
16.32.4 PRODUCT PORTFOLIO 1107
16.32.5 RECENT DEVELOPMENT 1108
16.33 TVARDI THERAPEUTICS 1109
16.33.1 COMPANY SNAPSHOT 1109
16.33.2 PIPELINE PRODUCT PORTFOLIO 1109
16.33.3 RECENT DEVELOPMENT/NEWS 1110
16.34 VERTEX PHARMACEUTICALS INCORPORATED 1111
16.34.1 COMPANY SNAPSHOT 1111
16.34.2 REVENUE ANALYSIS 1111
16.34.3 PRODUCT PORTFOLIO 1112
16.34.4 RECENT DEVELOPMENT 1113
16.35 VIKING THERAPEUTICS 1115
16.35.1 COMPANY SNAPSHOT 1115
16.35.2 REVENUE ANALYSIS 1115
16.35.3 PIPELINE PRODUCT PORTFOLIO 1115
16.35.4 RECENT DEVELOPMENT 1116
17 QUESTIONNAIRE 1117
18 RELATED REPORTS 1121